Open AccessInvited commentary: When and how to initiate systemic therapy in treating favorable risk metastatic renal cell carcinoma
Author(s) -
Takahiro Inoue
Publication year - 2021
Publication title -
current urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.476
H-Index - 13
eISSN - 1661-7657
pISSN - 1661-7649
DOI - 10.1097/cu9.0000000000000052
Subject(s) - medicine , sunitinib , axitinib , renal cell carcinoma , nivolumab , pembrolizumab , oncology , cancer , immunotherapy